BioDelivery Sciences (BDSI) Cash Flow Statement

Click line-items for a historical chart and %

Net (loss) income	-51.2M
Depreciation and amortization
Derivative gain
Stock-based compensation expense	11.6M
Intangible license impairment
Gain on settlement
Accounts receivable	-601K
Prepaid expenses and other assets	-537K
Accounts payable and accrued expenses	-662K
Deferred revenue	47K
Income tax payable
Net cash flows used in operating activities
Purchase of equipment	-316K
Purchase of intangible assets
Net cash flows from investing activities
Proceeds from issuance of common stock	2.46M
Proceeds from exercise of stock options	297K
Proceeds from exercise of warrants	0
Change in amounts due to related parties
Net cash flows from financing activities
Net change in cash and cash equivalents	-38.88M
Cash and cash equivalents at beginning of period	83.56M
Cash and cash equivalents at end of period	44.68M

Entities mentioned with BDSI

View All Entities